medigraphic.com
Instituto Nacional de Salud Pública

2026, Number 1

<< Back Next >>

salud publica mex 2026; 68 (1)

Bolsas de nicotina, un posible problema de salud pública emergente

Hernández-Pérez MA, Rodríguez-Barreto OM, Pérez-Padilla JR, Centeno-Sáenz GI

Language: Spanish
References: 36
Page: 91-96
PDF size: 256.94 Kb.


ABSTRACT

Nicotine pouches (NPs) have entered the Mexican national market. Their composition includes cellulose, flavorings, buffering acids, and nicotine salts that dissolve in the mouth and are absorbed through the gums and mucosa. NPs use is associated with the development of nicotine addiction and the appearance of lesions in the oral cavity. A possible increased risk of cancer associated with nitrosamines in these products has also been described, along with long-term adverse effects from nicotine exposure such as metabolic problems, chronic inflammation, and cognitive impairment. In this context, and considering their growing popularity, NPs could pose a significant risk to public health, particularly in adolescents and young adults, by acting as an initiation pathway toward nicotine addiction and promoting the renormalization of nicotine use, including that of regular cigarettes.


REFERENCES

  1. Kramer RD, Park-Lee E, Marynak KL, Jones JT, Sawdey MD, CullenKA. Nicotine pouch awareness and use among youth, national youthtobacco survey, 2021. Nicotine Tob Res. 2023;25(9):1610-1613. https://doi.org/10.1093/ntr/ntad080

  2. Mallock-Ohnesorg N, Rabenstein A, Stoll Y, Gertzen M, Rieder B, MalkeS, et al. Small pouches, but high nicotine doses—nicotine delivery andacute effects after use of tobacco-free nicotine pouches. Front Pharmacol.2024;15:1-11. https://doi.org/10.3389/fphar.2024.1392027

  3. Patwardhan S, Fagerström K. Nicotine pouches- a research and regulatorypolicy agenda to maximise public health benefits and minimise harms.Qeios. 2021;1-16. https://doi.org/10.32388/L4TIAF.3

  4. Nicotine pouches. [Internet]. Centers for Disease Control and Prevention;2025 [citado marzo 23, 2025]. Disponible en: https://www.cdc.gov/tobacco/nicotine-pouches/index.html

  5. Ling PM, Hrywna M, Talbot EM, Lewis MJ. Tobacco-derived nicotinepouch brands and marketing messages on internet and traditionalmedia: content analysis. JMIR Form Res. 2023;7:1-9. https://doi.org/10.2196/39146

  6. Stanfill S, Tran H, Tyx R, Fernandez C, Zhu W, Marynak K, et al.Characterization of Total and unprotonated (free) nicotine content ofnicotine pouch products. Nicotine Tob Res. 2021;23(9):1590-6. https://doi.org/10.1093/ntr/ntab030

  7. Lee J, Merenda F, Weinberger AH. Receiving coupons and discountsfor nicotine pouches is associated with current use of nicotine pouchesamong United States adults: results from the population assessment oftobacco and health (PATH) study wave 7 (2022-2023). Drug AlcoholDepend Rep. 2025;16:1-5. https://doi.org/10.1016/j.dadr.2025.100370

  8. Hoffmann D, Brunnemann KD, Prokopczyk B, Djordjevic MV. TobaccospecificN-nitrosamines and arecaderived n-nitrosamines: Chemistry,biochemistry, carcinogenicity, and relevance to humans. J Toxicol EnvironHealth. 1994;41(1):1-52. https://doi.org/10.1080/15287399409531825

  9. Mallock N, Schulz T, Malke S, Dreiack N, Laux P, Luch A. Levels of nicotineand tobacco-specific nitrosamines in oral nicotine pouches. Tob Control.2024;33:193-199. https://doi.org/10.1136/tobaccocontrol-2022-057280

  10. Cruz-Cano R, Rangel-Gomez M, Van Wagoner C, Kidanu A, BrinkmanMC, Clark PI. The acceptability of smokeless tobacco products dependson nicotine levels. Addict Behav Rep. 2019;10:1-8. https://doi.org/10.1016/j.abrep.2019.100217

  11. Picciotto MR, Kenny PJ. Molecular mechanisms underlying behaviorsrelated to nicotine addiction. Cold Spring Harb Perspect Med.2013;3(1):1-12. https://doi.org/10.1101/cshperspect.a012112

  12. Oliver AJ, Jensen JA, Vogel RI, Anderson AJ, Hatsukami DK. Flavoredand nonflavored smokeless tobacco products: Rate, pattern of use, andeffects. Nicotine Tob Res. 2013;15(1):88-92. https://doi.org/10.1093/ntr/nts093

  13. Valentine G, Sofuoglu M. Cognitive effects of nicotine: recent progress.Curr Neuropharmacol. 2018;16(4):403-14. https://doi.org/10.2174/1570159X15666171103152136

  14. Newhouse PA, Potter AS, Dumas JA, Thiel CM. Functional brainimaging of nicotinic effects on higher cognitive processes. Biochem Pharmacol.2011;82(8):943-951. https://doi.org/10.1016/j.bcp.2011.06.008

  15. Feng D, Yuan K, Li Y, Cai C, Yin J, Bi Y, et al. Intra-regional and interregionalabnormalities and cognitive control deficits in young adultsmokers. Brain Imaging Behav. 2016;10(2):506-16. https://doi.org/10.1007/s11682-015-9427-z

  16. Colyer-Patel K, Kuhns L, Weidema A, Lesscher H, Cousijn J. Agedependenteffects of tobacco smoke and nicotine on cognition and thebrain: A systematic review of the human and animal literature comparingadolescents and adults. Neurosci Biobehav Rev. 2023;146:1-29. https://doi.org/10.1016/j.neubiorev.2023.105038

  17. Lunell E, Fagerström K, Hughes J. Pharmacokinetic comparison of anovel non-tobacco-based nicotine pouch (ZYN®) with conventional,tobacco-based Swedish snus and American moist snuff. Nicotine Tob Res.2020;22(10):1757-63. https://doi.org/10.1093/ntr/ntaa068/5823724

  18. Grandolfo E, Ogden H, Fearon IM, Stevenson M, Weaver S, Nahde T.Tobacco-free nicotine pouches and their potential contribution to tobacco harm reduction: a scoping review. Cureus. 2024;16(2):1-27. https://doi.org/10.7759/cureus.54228

  19. Lee PN, Fry JS, Ljung T. Estimating the public health impact hadtobacco-free nicotine pouches been introduced into the US in 2000.BMC Public Health. 2022;22(1):1-11. https://doi.org/10.1186/s12889-022-13441-0

  20. Cullen JW, Blot W, Henningfield J, Boyd G, Mecklenburg R, MasseyMM. Health consequences of using smokeless tobacco: summary of theAdvisory Committee’s report to the Surgeon General. Public Health Rep.1986;101(4):355-73 [citado marzo 23, 2025]. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC1477739/

  21. Counotte DS, Spijker S, Van de Burgwal LH, Hogenboom F, SchoffelmeerAN, De Vries TJ, et al. Long-lasting cognitive deficits resultingfrom adolescent nicotine exposure in rats. Neuropsychopharmacology.2009;34(2):299-306. https://doi.org/10.1038/npp.2008.96

  22. Xiang S, Jia T, Xie C, Cheng W, Chaarani B, Banaschewski T, et al.Association between vmPFC gray matter volume and smoking initiation inadolescents. Nat Commun. 2023;14(1):1-13. https://doi.org/10.1038/s41467-023-40079-2

  23. Hajat C, Stein E, Ramstrom L, Shantikumar S, Polosa R. The healthimpact of smokeless tobacco products: a systematic review. Harm ReductJ. 2021;18(1):1-21. https://doi.org/10.1186/s12954-021-00557-6

  24. Stepanov I, Hecht SS, Ramakrishnan S, Gupta PC. Tobacco-specific nitrosaminesin smokeless tobacco products marketed in India. Int J Cancer.2005;116(1):16-9. https://doi.org/10.1002/ijc.20966

  25. Niaz K, Maqbool F, Khan F, Bahadar H, Ismail-Hassan F, Abdollahi M.Smokeless tobacco (paan and gutkha) consumption, prevalence, andcontribution to oral cancer. Epidemiol Health. 2017;39:1-11. https://doi.org/10.4178/epih.e2017009

  26. Luo J, Ye W, Zendehdel K, Adami J, Adami HO, Boffetta P, et al. Oraluse of Swedish moist snuff (snus) and risk for cancer of the mouth, lung,and pancreas in male construction workers: a retrospective cohort study.The Lancet. 2007;369(9578):2015-20. https://doi.org/10.1016/S0140-6736(07)60678-3

  27. Rungraungrayabkul D, Gaewkhiew P, Vichayanrat T, Shrestha B, BuajeebW. What is the impact of nicotine pouches on oral health: a systematicreview. BMC Oral Health. 2024;24(1):1-10. https://doi.org/10.1186/s12903-024-04598-8

  28. Valen H, Becher R, Vist GE, Holme JA, Mdala I, Elvsaas IØ, et al. Asystematic review of cancer risk among users of smokeless tobacco(Swedish snus) exclusively, compared with no use of tobacco. Int J Cancer.2023;153(12):1942-53. https://doi.org/10.1002/ijc.34643

  29. Nordenvall C, Nilsson PJ, Ye W, Andersson TML, Nyrén O. Tobacco useand cancer survival: A cohort study of 40,230 Swedish male constructionworkers with incident cancer. Int J Cancer. 2013;132(1):155-61. https://doi.org/10.1002/ijc.27587

  30. Nordenvall C, Nilsson PJ, Ye W, Nyrén O. Smoking, snus use andrisk of right- and left-sided colon, rectal and anal cancer: A 37-year follow-up study. Int J Cancer. 2011;128(1):157-65. https://doi.org/10.1002/ijc.25305

  31. Zendehdel K, Nyrén O, Luo J, Dickman PW, Boffetta P, EnglundA, et al. Risk of gastroesophageal cancer among smokers and users ofScandinavian moist snuff. Int J Cancer. 2008;122(5):1095-99. https://doi.org/10.1002/ijc.23076

  32. Brembach TC, Sabat R, Witte K, Schwerdtle T, Wolk K. Molecular andfunctional changes in neutrophilic granulocytes induced by nicotine: asystematic review and critical evaluation. Front Immunol. 2023;14:1-21.https://doi.org/10.3389/fimmu.2023.1281685

  33. Rathi A, Khanam A, Khan H, Aatif M, Farhan M, Sharma RK, et al. Acomprehensive review: role of smokeless tobacco consumption as a riskfactor for diabetes mellitus. Acta Diabetol. 2025;62(4):453-67. https://doi.org/10.1007/s00592-025-02453-y

  34. Af Geijerstam P, Joelsson A, Rådholm K, Nyström FH. Cardiovascularand metabolic changes following 12 weeks of tobacco and nicotine pouchcessation: a Swedish cohort study. Harm Reduct J. 2025;22(1):1-12. https://doi.org/10.1186/s12954-025-01195-y

  35. Menshov VA, Trofimov AV, Zagurskaya AV, Berdnikova NG, YablonskayaOI, Platonova AG. Influence of nicotine from diverse delivery tools on theautonomic nervous and hormonal systems. Biomedicines. 2022;10(1):1-30.https://doi.org/10.3390/biomedicines10010121

  36. Convenio Marco de la OMS para el Control del Tabaco. Ginebra: OPS/OMS, 2005 [citado octubre 2025]. Disponible en: https://www.paho.org/es/documentos/convenio-marco-oms-para-control-tabaco37. Secretaría de Salud. 295. Conasama alerta por uso de bolsas de nicotina.[Internet]. México: Secretaría de Salud, 2024 [citado marzo 23, 2025].Disponible en: https://www.gob.mx/salud/prensa/295-conasama-alertapor-uso-de-bolsas-de-nicotina




2020     |     www.medigraphic.com